Absolutely, I agree with that, StockFollower: evidence of Direct creating a systemic response in the patients and the stock price will go wild.
In particular, we have the patients from the original PR that had evidence of cancer cell destruction -- but AF challenged the data because under the RECIST criteria, they hadn't shrunk enough to indicate a response.
If weeks later those same patients now have tumor shrinkage that does qualify as a response under the RECIST criteria, then all criticism about not using the RECIST criteria goes away.
I had posed this question before - if a tumor is destroyed, will it eventually shrink? Reefrad answered that in post 15604, saying that eventually it would.
So if DCVax-Direct is showing great results, highlighting the success of those patients that AF said hadn't responded would be an ideal PR.